NHS pauses hormone referrals for teens

LONDON, England — NHS England has paused new prescriptions and referrals for masculinising or feminising (cross‑sex) hormones for under‑18s, citing evidence reviews that found insufficient proof of safety or benefit. The decision and consultation were confirmed across BBC News, The Guardian, Sky News, the NHS England consultation guide, the NHS England evidence review page, and a UK Parliament written statement. We prioritize facts independently verified across multiple reputable sources.

Mutually confirmed facts across these sources include:

• NHS England is pausing new prescriptions/referrals for masculinising or feminising hormones for under‑18s, including 16–17‑year‑olds, with immediate effect during consultation.
• The pause follows evidence reviews concluding the available evidence is limited or weak, leaving uncertainty about benefits and harms for adolescents.
• A 90‑day public consultation on revised clinical policy began on 9 March 2026, proposing that these hormones not be routinely commissioned for under‑18s.
• Patients aged 16–17 already receiving NHS prescriptions may continue, but each case must be reviewed individually with clinicians.

Additional Details Reported

The consultation guide notes current policy allowed limited prescriptions for 16–17‑year‑olds only under strict criteria and specialist oversight, and that NHS England will decide next steps after the consultation closes.

The written statement says the pause remains in place until a final policy is determined following feedback.

The Cass Review into children’s gender care is cited as the catalyst for commissioning the new evidence reviews and policy reconsideration.

How we report: We select the day’s most important stories, confirm facts across multiple reputable sources, and avoid anonymous sourcing. Our goal is clear, balanced coverage you can trust—because transparency and verification matter for informed readers.